Evidence map›Paper›PMID 39565471›Full record

ReviewClinical and experimental nephrology2025

Transcatheter arterial embolization therapy in patients with polycystic kidney disease and liver disease: review from case series.

Yoshifumi Ubara, Tatsuya Suwabe, Naoki Sawa

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Yoshifumi UbaraNephrology Center and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, 2-2-2, Toranomon, Minato, Tokyo, Japan. ubara@toranomon.gr.jp.
Tatsuya SuwabeNephrology Center and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, 2-2-2, Toranomon, Minato, Tokyo, Japan.
Naoki SawaNephrology Center and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, 2-2-2, Toranomon, Minato, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have achieved good results of renal transarterial embolization (TAE) therapy as an alternative to surgical nephrectomy to decrease renal size in autosomal polycystic kidney disease (ADPKD) patients with enlarged kidneys, but only in patients on dialysis. Renal transplantation is another treatment option, and patients who receive a donor kidney have achieved a reduction in kidney size after surgery. TAE has also been used in polycystic liver disease (PCLD), an extrarenal lesion of ADPKD. Although TAE is effective in some PCLD patients, others develop hepatomegaly, which leads to liver cyst infection and liver failure. Recently, liver transplantation has started to be performed in such patients. Initially, living donor liver transplants were performed from family members, but in 2010, deceased donor liver transplantation became available. This article gives an overview of the history of TAE for ADPKD and PCLD on the basis of our experience.

Indexed as

CystsEmbolization, TherapeuticLiver DiseasesPolycystic Kidney, Autosomal DominantPolycystic Kidney DiseasesHumansLiver TransplantationMaleTreatment OutcomeAutosomal dominant polycystic kidney disease (ADPKD)Polycystic kidney diseasePolycystic liver diseaseTranscatheter arterial embolization therapy (TAE)

Identifiers

PMID39565471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.